Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study
Phase of Trial: Phase I
Latest Information Update: 27 May 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms Pembro/IORT
- 22 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 May 2017 Status changed from not yet recruiting to recruiting.
- 02 Dec 2016 New trial record